Tomoaki Yoh

Dr. Tomoaki Yoh


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Annals of Surgery
Verified
Journal Article
Closed access
TYTomoaki Yoh
Tomoaki Yoh
SSSatoru Seo
Satoru Seo
KTKojiro Taura
Kojiro Taura
KIKohta Iguchi
Kohta Iguchi
SOSatoshi Ogiso
Satoshi Ogiso
SUShinji Uemoto
Shinji Uemoto
Objective: To evaluate the long-term outcomes of surgery for recurrent hepatocellular carcinoma (HCC). Background: HCC recurs with high incidence after liver resection. Little is known about long-term outcomes of patients undergoing surgery for recurrent HCC. Methods: Among 989 patients who underwent R0/R1 liver resection for HCC between 1995 and 2014, 676 patients who exhibited recurrence were included. Repeat surgery was performed in 128 patients (RS group), and not in the remaining 548 patients (NS group). Prognostic value after repeat surgery was evaluated by comparing survival after recurrence (SAR) between the RS and NS groups. Subgroup analyses according to the 3 recurrence patterns [intrahepatic recurrence (IHR), extrahepatic recurrence (EHR), and intra plus extrahepatic recurrence (IHR + EHR)] were performed. Results: Seventy-three of 430 patients (17.0%) with IHR, 17 of 57 patients (29.8%) with EHR, and 38 of 189 patients (20.1%) with IH + EHR underwent repeat surgery. Compared with the NS group, the RS group had better liver function and their time to recurrence was significantly longer (16.5 vs 11.4 months; P < 0.001). In the overall and 3 recurrence patterns, the 5-year SAR rate was better in the RS group compared with the NS group (RS vs NS group; overall, 53.0% vs 25.7%; IHR, 73.8% vs 37.2%; EHR, 30.0% vs 0%; IHR + EHR, 34.1% vs 10.6%; all P < 0.001, respectively). On multivariate analysis, repeat surgery was identified as an independent factor for better SAR (P < 0.001). Conclusion: Surgery for recurrent HCC may yield long-term survival for not only IHR but also for EHR in selected patients.

1 December 2019 in Surgery
Verified
Journal Article
Closed access
TYTomoaki Yoh
Tomoaki Yoh
FCFrançois Cauchy
François Cauchy
BRBertrand Le Roy
Bertrand Le Roy
SSSatoru Seo
Satoru Seo
KTKojiro Taura
Kojiro Taura
OSOlivier Soubrane
Olivier Soubrane

1 February 2020 in HPB
Verified
Journal Article
Closed access
BRBertrand Le Roy
Bertrand Le Roy
AGArnaud Gallon
Arnaud Gallon
FCFrancois Cauchy
Francois Cauchy
BPBruno Pereira
Bruno Pereira
JGJohan Gagnière
Johan Gagnière
PCPascal Chabrot
Pascal Chabrot

7 December 2017 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
TYTomoaki Yoh
Tomoaki Yoh
EHEtsuro Hatano
Etsuro Hatano
SSSatoru Seo
Satoru Seo
YOYukihiro Okuda
Yukihiro Okuda
HFHiroaki Fuji
Hiroaki Fuji
SUShinji Uemoto
Shinji Uemoto

1 September 2021 in HPB
Verified
Journal Article
Closed access
KYKenji Yoshino
Kenji Yoshino
TYTomoaki Yoh
Tomoaki Yoh
Kojiro TauraKojiro Taura
Kojiro Taura
SSSatoru Seo
Satoru Seo
RCRuben Ciria
Ruben Ciria
JBJavier Briceño-Delgado
Javier Briceño-Delgado

14 September 2016 in Liver Cancer
Verified
Journal Article
Open access
PDF file
TYTomoaki Yoh
Tomoaki Yoh
EHEtsuro Hatano
Etsuro Hatano
KYKenya Yamanaka
Kenya Yamanaka
TNTakahiro Nishio
Takahiro Nishio
SSSatoru Seo
Satoru Seo
SUShinji Uemoto
Shinji Uemoto
Backgrounds: Prognosis for patients with advanced intrahepatic cholangiocarcinoma (ICC) with intrahepatic metastasis (IM), vascular invasion (VI), or regional lymph node metastasis (LM) remains poor. The aim of this study was to clarify the indications for surgical resection for advanced ICC. Methods: We retrospectively divided 213 ICC patients treated at Kyoto University Hospital between 1993 and 2013 into a resection (n=164) group and a non-resection (n=49) group. Overall survival was assessed after stratification for the presence of IM, VI, or LM. Results: Overall median survival times (MSTs) for the resection and non-resection groups were 26.0 and 7.1 months, respectively (p<0.001). After stratification, MSTs in the resection and non-resection groups, respectively, were 18.7 vs. 7.0 months for patients with IM (p<0.001), 23.4 vs. 5.7 months for those with VI (p<0.001), and 12.8 vs. 5.5 months for those with LM (p<0.001). Conclusion: When macroscopic curative resection is possible, surgical resection can be justified for some advanced ICC patients with IM, VI, or LM.